The 10 most recent market catalysts affecting $KNSA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Goldman Sachs analyst Paul Choi maintained a 'Buy' rating on Kiniksa Pharmaceuticals (KNSA) and raised the price target from $75 to $90. This action indicates a strengthened positi…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107
JP Morgan analyst Anupam Rama has maintained an 'Overweight' rating on Kiniksa Pharmaceuticals (KNSA) and raised the price target from $72 to $107. This substantial increase in the…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98
Canaccord Genuity's analyst Edward Nash has maintained a 'Buy' rating on Kiniksa Pharmaceuticals and significantly raised the price target from $64 to $98. This action signals incr…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99
Wedbush analyst David Nierengarten maintained an 'Outperform' rating for Kiniksa Pharmaceuticals and significantly raised the price target from $72 to $99. This action indicates a …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100
Citigroup analyst Geoff Meacham has maintained a 'Buy' rating on Kiniksa Pharmaceuticals and raised the price target from $60 to $100. This substantial increase in the price target…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Kiniksa Pharmaceuticals International shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a strong positive corporate catalyst for Kiniksa Pharmaceuticals. Better-than-expected earnings and, more importantly, a raised long-term sales guidance (F…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate
Kiniksa Pharmaceuticals announced Q2 earnings of $0.30 per share, surpassing the analyst consensus of $0.27 by 11.11%, and representing a 30.43% increase year-over-year. Additional…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (KNSA) filed an 8-K to announce a substantial increase in its sales outlook for fiscal year 2026. The company raised its guidance from $930M-$945M to $980M-…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 65
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75
Goldman Sachs analyst Paul Choi has maintained a 'Buy' rating on Kiniksa Pharmaceuticals (KNSA) and raised the price target from $60 to $75. This upgrade signals increased confiden…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74
Wells Fargo analyst Eva Fortea Verdejo maintained an 'Overweight' rating on Kiniksa Pharmaceuticals (KNSA) and significantly raised the price target from $57 to $74. This upward re…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.